Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia

Dario Eklund, Chief Executive Officer of Santhera, said: “This agreement will enable more children to access this important DMD treatment, and is the latest in a series of global agreements secured in 2025. We look forward to working closely with Biomedica in the months ahead.”